JPMorgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health (PAHC) to Overweight from Neutral with a price target of $35, up from $25. The firm says the company continues to deliver strong results while the integration of the Zoetis medicated feed additive business is exceeding expectations. Solid animal health portfolio trends should continue, supported by strong customer demand and healthy industry fundamentals, the analyst tells investors in a research note. JPMorgan sees a favorable setup from here.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health price target raised to $26 from $21 at Morgan Stanley
- Phibro Animal Health upgraded to Neutral from Underperform at BNP Paribas Exane
- Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth
- Phibro Animal Health Reports Strong Q3 Results
- Phibro Animal Health price target raised to $21 from $20 at Morgan Stanley